PSGR is a novel member of the G-protein-coupled olfactory receptor family. Our initial report showed predominant expression of the PSGR in human prostate gland and significant alterations of PSGR expression in primary prostate cancer (CaP) specimens. The aim of this study was to provide in-depth evaluations of the expression profile of PSGR in prostatic epithelial cells of CaP patients and to evaluate the association of PSGR expression characteristics with clinico-pathologic features. In total, 220 RNA specimens, from laser capture microdissected paired benign and malignant prostatic epithelial cells of 110 CaP patients, were analyzed for PSGR expression by quantitative real-time PCR. The differential expression of PSGR between the prostatic epithelial cells of malignant and benign glands was statistically significant (Po0.0001). Comparison of PSGR expression between paired benign and tumor cells revealed prostate tumor cell-specific overexpression in 67.2% of tumor specimens (74 of 110), decreased expression in 20.9% of tumor specimens (23 of 110) and no difference of PSGR expression between tumor and normal cells in 11.8% of specimens (13 of 110). In representative cases, PSGR expression patterns were independently confirmed by in situ RNA hybridization. The PSGR overexpression associated with higher percentage of pathologic stage, pT3, and a higher level of preoperative serum PSA. CaP cells of African-American CaP patients exhibited about two-fold increase of PSGR expression in comparison to the Caucasian American CaP patients. Strikingly high-percentage CaP cells overexpress PSGR warrants further studies of PSGR expression alterations to define subsets of CaPs.
Introduction
Prostate cancer (CaP) is the most common malignancy in American men and the second leading cause of cancer mortality. 1 Its outward symptoms are not always apparent, so when left untreated it may metastasize to other parts of the body or vital organs. When this happens, the patient has fewer treatment options than they would have if their disease had been discovered earlier. Blood-Prostate-Specific Antigen (PSA) test along with other diagnostic tools has been very successful in the early detection of CaP. 1 However, wide spectrum of biologic behavior exhibited by prostatic neoplasms poses a difficult problem in predicting the clinical course for the individual patient. [2] [3] [4] [5] Translational potentials of prostate-specific genes/proteins as biomarkers of CaP onset/progression and as therapeutic targets of CaP are highly significant. Along these lines, our laboratory is focusing on the identification and evaluations of genes that are not only prostate specific but are also overexpressed in CaP.
Our previous report defined PSGR as a prostate tissuespecific gene and suggested the potential role of PSGR expression alterations in CaP due to its overexpression in prostate cancers. 6 The open reading frame (ORF) of PSGR cDNA encoded a 320 amino-acid protein with a predicted molecular mass of 35.4 kDa. The PSGR-ORF revealed intriguing homology (B50% identity and B70% similarity) to seven-transmembrane G-proteincoupled odorant receptor (OR) family. ORs belong to the superfamily of G-protein-coupled receptors (GPCRs) that are transmembrane proteins mediating cellular responses to diverse extracellular stimuli, including light, neurotransmitters, hormones and odorants. 7 GPCRs are the largest gene family known to exist in a given animal genome. GPCRs also dominate as drug targets in pharmaceutical industry. Our evaluation of PSGR expression in 50 different normal human adult and fetal tissues showed the presence of PSGR mRNA only in human prostate tissue. 6 While independent reports have confirmed predominant expression of PSGR in human prostate, 8, 9 in one study where specific regions of human brain were analyzed. PSGR expression was also noted in the olfactory zone and the medula oblongata. 10 In order to define the utility of PSGR expression as a biomarker and/or therapeutic target for CaP, we have now performed a comprehensive study of the PSGR expression in laser capture microdissected epithelial cells from benign and malignant prostate tissues of 110 CaP patients who had primary CaP and were treated by radical prostatectomy (RP). The evaluation of the association of the quantitative expression characteristics of PSGR to the clinico-pathologic features of the CaP patients is reported herein.
Materials and methods

Prostate tissue specimens and pathologic evaluation
Matched CaP and normal prostate tissues were derived from RP of 110 CaP patients treated at Walter Reed Army Medical Center (WRAMC) under an IRB-approved protocol. The genitourinary pathologist (IAS) was present in the operating room to immediately accept the prostate gland from the urologists. If a palpable tumor was present, the surface overlying it was painted with black ink and a wedge from the center was immediately embedded in Tissue-tek OCT (Miles Inc., Diagnostics Division Elkhart, IN, USA) and frozen at À701C The volume of biopsy specimens was about 1 Â 0.5 Â 0.5 cm 3 . Ten micron frozen sections were prepared and kept frozen until used. One set of slides was stained with hematoxylin and eosin (H&E) for pathologic evaluation.
Clinical information
All RP patients in this study are enrolled in the Department of Defense Center for Prostate Disease Research (CPDR) Triservice Multicenter Longitudinal CaP Database. Standardized data forms were used prospectively to collect demographic, clinical and pathologic stage, biopsy and RP grade, laboratory and followup information. RP specimens were processed as 2.25 mm step-sectioned whole mounts at the Armed Forces Institute of Pathology using a standardized protocol and data were also collected prospectively as part of the CPDR database.
Laser capture microdissection and quantitative reverse transcription polymerase chain reaction assays Prostate epithelial cells from malignant and benign gland were microdissected by a pathologist (BF) using Laser Capture Microdissection (LCM) equipment according to the protocol provided by the manufacturer (Arcturus Engineering, Mountain View, CA, USA). The most widespread Gleason pattern in the frozen prostate specimen was sampled by LCM consistently in all patients. Total RNA was extracted from the microdissected cells with RNAzol (TEL-TEST, INC., Friendswood, TX, USA) according to manufacturer's protocol and quantified with Fluorometer (Bio-Rad, Hercules, CA, USA). RNA (220 specimens) from paired normal and tumor specimens from 110 patients were analyzed by quantitative reverse transcription polymerase chain reaction (QRT-PCR) by 7700 sequence detection system (PE Applied Biosystems, Foster, CA, USA). RT-PCR was conducted using 0.1 ng of total RNA from each normal or tumor sample. Reverse transcription reactions were carried out at 421C with or without M-MLV reverse transcriptase for 30 min. PCR primers for PSGR were 5 0 CATGGCCTTTGACCGTTATGT 3 0 : 5 0 GCCAATCTGG GCTGTTACTGTAT 3 0 using a FAM labeled probe (ACCCACTGCGCCATGCTGCA). Glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression was detected as the internal control. PCR reactions were performed in 50 ml volumes containing the manufacturer's recommended universal reagent (PE Applied Biosystems, Foster, CA, USA), PSGR primers (final concentration 300 nM each) and probe (final concentration 100 nM), and GAPDH primers/probe mixture (PE Applied Biosystems, Foster, CA, USA). Amplification consisted of 45 cycles using denaturing (15 s. 951C) and annealing/extension (60 s 601C) steps. Results were plotted as average cycle threshold (cT) values for each duplicate sample minus the average duplicate values for GAPDH. Differences of PSGR expression between tumor and normal samples were calculated using 2exp(cT tumorcT normal ) formula and were expressed as the fold change of PSGR expression in tumor cells in comparison to matched normal cells from the same patient. The tumor specimens with different PSGR expression characteristics were grouped as: overexpression in tumor tissue (T4N), defined as 1 þ (1.5-5-fold), 2 þ (5.1-10-fold), 3 þ (10.1-20-fold) and 4 þ (420-fold); reduced expression in tumor tissue (ToN), defined as 1-(1.5-5-fold), 2-(5.1-10-fold), 3-(10.1-20-fold) and 4-(420-fold); and no change (T ¼ N), refers to the difference of PSGR expression between T and N as o1.5-folds. No detectable PSGR expression in one of the tumor/normal specimen pair was scored as 4 þ for increased or 4-for decreased expression.
In situ hybridization
In situ hybridizations with a PSGR ribo probe 6 were performed on frozen sections from 10 CaP patients. These frozen sections corresponded to the same tissues used for LCM and QRT-PCR and represented varying degree (from 1 þ to 4 þ ) of PSGR expression by QRT-PCR. The slides were evaluated under a Leica microscope and Open-Lab software (Improvision, Lexington, MA, USA). Based on the density of the staining, PSGR expression levels by in situ hybridization were graded as low, medium and high and were compared with the results from QRT-PCR.
Statistical analysis
Statistical analysis was performed with the SAS software package. Boxplot was used to show the difference of normalized PSGR expression between tumor and normal PSGR overexpression in CaP LL Xu et al tissue. The association between normalized PSGR expression and clinico-pathological features was analyzed by using w 2 tests. Po0.05 was considered as statistically significant.
Results
Quantitation of PSGR expression in laser capture microdissected prostate epithelial cells from malignant and benign prostate tissues of prostate cancer patients Our earlier study showed restricted PSGR expression in epithelial cells of the human prostate tissues. 6 Since LCM allows dissection of pure target cells, [11] [12] [13] we have performed quantitative evaluation of PSGR in LCM derived prostatic epithelial cells from matched malignant and benign prostate tissues of 110 CaP patients. A representative QRT-PCR analysis of PSGR and GAPDH is shown in Figure 1 . The overall cT values of PSGR are in the range of 26-37 in tumor cells and 27-39 in normal prostate epithelial cells ( Figure 1a) . As PSGR is an intronless gene, precaution was taken to identify signals that might result from possible contamination of genomic DNA in RNA specimens. Our data showed that up to 50 cycles there were no amplifications in the no-RT samples (Figure 1c) , indicating the amplification PSGR from genomic DNA, if any, was very low and would not affect the overall interpretation of the data. The DcT of PSGR, which represented the expression level, was The normalized expression levels of PSGR in each of the 110 normal specimens and 110 tumor specimens, as calculated by 2exp(cT PSGR -cT GAPDH ), were also evaluated (Figure 3) . Although the level of PSGR expression varied widely between the normal specimens or between the tumor specimens, the statistical analyses showed that the relative expression of PSGR in normal and tumor cells were 1.62725.65 and 13.52734.16, respectively. There was a significant difference of PSGR expression between normal and tumor cells (P ¼ 0.0001).
The in situ hybridization analysis also showed the overexpression of PSGR in CaP (Figure 4) was consistent with the data of QRT-PCR. Overall, the expression levels of PSGR in prostate tissues detected by in situ hybridization matched with the results derived from QRT-PCR.
PSGR expression and clinical correlation
PSGR was first reported by our laboratory as a prostatespecific GPCR with increased expression in CaP tissues. 6 In a larger study including new cohort of patients, we further demonstrate that PSGR is overexpressed in 67% of CaP cells compared with the matched normal prostate cells. When these expression patterns were stratified by Figure 3 Relative expression level of PSGR mRNA in normal and malignant prostate tissues. PSGR expression was quantitatively evaluated and was normalized with the expression level of GAPDH in 110 pairs of normal and malignant prostate tissues. The P-value was calculated by the T-test. PSGR overexpression in CaP LL Xu et al organ-confined (pT2) and nonorgan-confined (pT3) disease, a higher percentage of tumor-associated PSGR overexpression was seen in pT3 (71.4%) vs pT2 (60.8%). As the T4N group has a small number of cases, we combined the ToN group and the T ¼ N group (TpN group). T4N group was also associated with higher percentage of patients with more advanced disease, with higher level of serum PSA and as African Americans (Table 1) . Pearson Correlation Coefficients analysis showed a significant correlation between tumor-associated cell PSGR expression level and serum PSA level (P ¼ 0.03). It was also revealed that PSGR expression in CaP cells in African-American CaP patients was 2.14-fold higher than that in Caucasian CaP patients (P ¼ 0.09, Figure 5 ). Wilcoxon rank sum test also indicated a higher expression of PSGR in CaP cells from African-American CaP patients (P ¼ 0.0795). Of the 27 African-American patients, four had PSA-recurrence. Of note, all the four patients who had PSA-recurrence were found overexpression of PSGR in their CaP tissues.
P<0.0001
Discussions
Molecular studies have shown a significant heterogeneity between multiple cancer foci present in a cancerous prostate gland. [14] [15] [16] [17] These studies have also documented that the metastatic lesions can arise from the cancer foci other than dominant tumors. [15] [16] [17] Approximately, 50-60% of patients treated with RP for localized prostate carcinomas are found to have microscopic disease that is not organ confined, and a significant portion of these patients relapse. 18 Therefore, identification and characterization of genetic alterations defining CaP onset and progression is crucial in understanding the biology and clinical course of disease. 5, 17 Despite recent intensive research investigations, much remains to be learned about specific molecular defects associated with CaP onset and progression. 5, [18] [19] [20] [21] [22] Our laboratory is focusing on the discovery of new biomarkers for CaP diagnosis, prognosis and treatment. These efforts resulted the identification of numerous prostate specific/abundance and/or CaP-associated genes. 6, [23] [24] [25] Among these is PSGR originally identified by our group. 6 In a larger cohort of study, we now demonstrate that PSGR is overexpressed in CaP cells (67%) compared with the matched normal prostate cells confirming our previous observations. While the manuscript was in publication, a similar study was published by Weng et al. 26 who also demonstrated the overexpression of PSGR in CaP and provided the evidence that PSGR is a potential marker for early CaP detection and diagnosis. In this report, we have utilized laser capture microdissected epithelial cells from benign and malignant prostate glands of the specimen of each patient specimen. Therefore, it is very comprehensive quantitative expression profile of PSGR in normal as well as tumor epithelium. Our study revealed that overexpression of PSGR had the trends that associate with more advanced disease and higher level of serum PSA. It is also worth noting that the PSGR expression level in CaP cells of African-American man (AAM) is higher than that of Caucasian. It has been suggested that AAM are at higher risk of CaP than any other ethnic group. 27, 28 The incidence of CaP in AAM may be twice as high as in Caucasian men, and the mortality is also disproportionately high. 27, 28 Efforts have been made to identify the molecule(s) that may play roles in the progression of the disease in AAM. 25, [29] [30] [31] Our findings that PSGR is overexpressed in CaP cells and the expression level is further higher in CaP cells from AAM may suggest the The patients were grouped into two groups: T4N ( 
